| __timestamp | BioMarin Pharmaceutical Inc. | Xencor, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 129764000 | 18516000 |
| Thursday, January 1, 2015 | 152008000 | 34140000 |
| Friday, January 1, 2016 | 209620000 | 51872000 |
| Sunday, January 1, 2017 | 241786000 | 71772000 |
| Monday, January 1, 2018 | 315264000 | 97501000 |
| Tuesday, January 1, 2019 | 359466000 | 118590000 |
| Wednesday, January 1, 2020 | 524272000 | 169802000 |
| Friday, January 1, 2021 | 470515000 | 7491000 |
| Saturday, January 1, 2022 | 483669000 | 8799000 |
| Sunday, January 1, 2023 | 577065000 | 253598000 |
| Monday, January 1, 2024 | 580235000 |
Data in motion
In the competitive landscape of biotechnology, understanding cost structures is crucial. BioMarin Pharmaceutical Inc. and Xencor, Inc. have shown distinct trajectories in their cost of revenue from 2014 to 2023. BioMarin's cost of revenue has surged by approximately 345%, peaking in 2023, reflecting its expanding operations and possibly increased production costs. In contrast, Xencor's cost of revenue, while more volatile, has seen a dramatic increase of over 1,270% in the same period, with a notable spike in 2023. This could indicate strategic investments in research and development or scaling of operations. The data highlights the dynamic nature of the biotech industry, where companies must balance innovation with cost efficiency. As BioMarin and Xencor continue to evolve, stakeholders should watch these trends closely to gauge future financial health and strategic direction.
Comparing Cost of Revenue Efficiency: Amgen Inc. vs Xencor, Inc.
Comparing Cost of Revenue Efficiency: Regeneron Pharmaceuticals, Inc. vs BioMarin Pharmaceutical Inc.
Cost of Revenue Comparison: Teva Pharmaceutical Industries Limited vs BioMarin Pharmaceutical Inc.
Cost of Revenue Trends: Teva Pharmaceutical Industries Limited vs Xencor, Inc.
Neurocrine Biosciences, Inc. vs Xencor, Inc.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Incyte Corporation and BioMarin Pharmaceutical Inc.'s Expenses
Cost of Revenue Trends: BioMarin Pharmaceutical Inc. vs ADMA Biologics, Inc.
Comparing Cost of Revenue Efficiency: BioMarin Pharmaceutical Inc. vs PTC Therapeutics, Inc.
BioMarin Pharmaceutical Inc. vs Ligand Pharmaceuticals Incorporated: Efficiency in Cost of Revenue Explored
BioMarin Pharmaceutical Inc. vs BioCryst Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Comparing SG&A Expenses: BioMarin Pharmaceutical Inc. vs Xencor, Inc. Trends and Insights
Cost of Revenue Trends: Agios Pharmaceuticals, Inc. vs Xencor, Inc.